STK-001 - Single Ascending Doses + STK-001 - Multiple Ascending Doses
Phase 1/2Completed 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Dravet Syndrome
Conditions
Dravet Syndrome
Trial Timeline
Jun 29, 2020 → Nov 14, 2023
NCT ID
NCT04442295About STK-001 - Single Ascending Doses + STK-001 - Multiple Ascending Doses
STK-001 - Single Ascending Doses + STK-001 - Multiple Ascending Doses is a phase 1/2 stage product being developed by Stoke Therapeutics for Dravet Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT04442295. Target conditions include Dravet Syndrome.
What happened to similar drugs?
2 of 12 similar drugs in Dravet Syndrome were approved
Approved (2) Terminated (3) Active (7)
Hype Score Breakdown
Clinical
9
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04442295 | Phase 1/2 | Completed |
Competing Products
15 competing products in Dravet Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ZX008 (Fenfluramine Hydrochloride) | UCB | Phase 3 | 40 |
| ZX008 (Fenfluramine Hydrochloride) | UCB | Phase 3 | 32 |
| ZX008 0.2 to 0.8 mg/kg/day + Cannabidiol | UCB | Phase 1 | 29 |
| fenfluramine | UCB | Approved | 50 |
| Fenfluramine Hydrochloride | UCB | Pre-clinical | 26 |
| ZX008 (Fenfluramine Hydrochloride) + Matching Placebo | UCB | Phase 3 | 40 |
| ZX008 (Fenfluramine Hydrochloride) | UCB | Phase 3 | 40 |
| fenfluramine | UCB | Phase 3 | 44 |
| ZX008 (Fenfluramine Hydrochloride) + Matching Placebo | UCB | Phase 3 | 40 |
| Clobazam | Lundbeck | Phase 3 | 29 |
| Clobazam + Placebo | Lundbeck | Phase 3 | 29 |
| Epidiolex 100 mg/mL Oral Solution | Jazz Pharmaceuticals | Approved | 47 |
| zorevunersen | Stoke Therapeutics | Phase 3 | 41 |
| zorevunersen (STK-001) | Stoke Therapeutics | Phase 2 | 33 |
| Clemizole HCl + Placebo | Harmony Biosciences | Phase 3 | 41 |